[1]Lemoine M. Non-alcoholic fatty liver disease: overview of the natural history[J]. Gastroentérologie Clinique et Biologique, 2009, 33(5): 398-404. [2]胡红心,周建英.非酒精性脂肪肝相关危险因素分析[J].中国实用医药,2014,9(35):5-6. [3]王悦之,张玉.CYP2E1与非酒精性脂肪肝[J].胃肠病学和肝病学杂志,2012,21(4):384-386. [4]石海燕,李珏宏,李昌平,等.NF-КB、血管紧张素Ⅱ-1型受体在大鼠非酒精性脂肪肝病中的作用及其机制[J].实用医学杂志,2015,31(2):197-200. [5]Zou Y, Li J, Lu C, et al. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis[J]. Life Sci, 2006, 79(11): 1100-1107. [6]Ascencio C, Torres N, Isoard-Acosta F, et al. Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats[J]. J Nutr, 2004, 134(3): 522-529. [7]秦艳,张晾,潘杰.高脂饮食对非酒精性脂肪肝影响机制研究进展[J].实用肝脏病杂志,2010,13(1):72-74. [8]Day CP,James OF.Steatohepatitis:a tale of two "hits"[J].Gastroenterology,1998,114(4):842-845. [9]Villeneuve JP, Pichette V. Cytochrome P450 and liver diseases[J]. Curr Drug Metab, 2004, 5(3): 273-282. [10]陈海姣,刘鹏飞,张伟,等.HIF-1α、NF-κB在大鼠不同程度非酒精性脂肪肝中的表达[J].世界华人消化杂志,2014,22(35):5480-5485. [11]Chtioui H, Semela D, Ledermann M, et al. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis[J]. Liver Int, 2007, 27(6): 764-771 [12]Peng X,Zhang P,Wang X,et al. Activation of IKK and MAPK by thymosin alpha1 hepatology[J].Ann N Y Acard Sci,2007,1112:339-350. [13]Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease[J]. Drug Metab Dispos, 2009, 37(10): 2087-2094. |